Why the study?
Do drug-eluting stents improve efficacy and safety compared to bare-metal stents in patients undergoing stent procedures?
Do drug-eluting stents improve efficacy and safety compared to bare-metal stents in patients undergoing stent procedures?
This review appraises the safety and efficacy of drug-eluting stents, highlighting their superiority in reducing in-stent restenosis while addressing concerns about late stent thrombosis.
Supports careful stent selection balancing restenosis benefit against thrombosis risk; leaves open long-term safety with newer generations.
Drug-eluting stents (DESs) have largely demonstrated their superiority to bare-metal stents (BMSs) with respect to in-stent restenosis. Since the US Food and Drug Administration (FDA) approved the first DES in 2003, there has been a significant increase in the use of these devices. They are used in 70-80% of all stent procedures worldwide. Nevertheless, safety concerns stemming from reports of increased risk of late stent thrombosis (ST) and myocardial infarction (MI) have tempered the enthusiasm that the advent of these stents originally generated. New generation DESs with novel polymers, antiproliferative drugs, and improved platforms are now approved and available for use. In this review we provide a critical appraisal, based on published clinical data, of the safety and efficacy of various DESs.
No takes yet. Share an insight, caveat, or question.
Maluenda et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: